Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,526 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Insulin Dependent Diabetes Mellitus Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Improving Relationships Using Motivational Interviewing

NCT05696964
View directory record Official record
Conditions
Physician-Patient Relations, Diabetes Mellitus, Type 2
Interventions
Motivational interviewing training enhanced with artificial intelligence
Behavioral
Lead sponsor
Wright State University
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

NCT00934414
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 15, 2026, 2:17 PM EDT
Not listed Not applicable Interventional

iCan Diabetes Self-management and Prevention Program

NCT05571436
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes
Interventions
iCan Diabetes Self-management and Prevention Support Group
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 15, 2026, 2:17 PM EDT
Withdrawn No phase listed Observational

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

NCT05102071
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
empagliflozin, metformin, sulfonylurea
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ridgefield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 15, 2026, 2:17 PM EDT
Not listed Not applicable Interventional

Go Girls! Fitness Support Group Intervention Effectiveness Study

NCT02117063
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Abnormal Weight Gain, Excess Weight, Insulin Resistance, Premature Adrenarche, Type 2 Diabetes Mellitus
Interventions
Go Girls! Fitness Support Group
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

NCT01177163
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, JNJ 28431754 300 mg/placebo, JNJ 28431754 100 mg/placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 15, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

NCT02053116
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 15, 2026, 2:17 PM EDT
Terminated Phase 4 Interventional Results available

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide (1 Mg Dose), Placebo
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06269107
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
IcoSema, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Concord, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Examining the Effects of Diet on Health With an Online Program

NCT01967992
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Behavioral: Low Carbohydrate, Ketogenic Diet, American Diabetes Association Diet, Mindfulness and Positive Affect Skills
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

NCT00110864
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PN2034, Insulin
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Waterbury, Connecticut • Hollywood, Florida • Longwood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Not applicable Interventional Results available

Michigan Men's Diabetes Project

NCT04760444
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Leader Diabetes Self-Management Support, Virtual Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 15, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Virtual Reality to Improve Medical Training

NCT07542834
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions
Cinematic Virtual Reality Training, Traditional Didactic Lecture
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 2:17 PM EDT
Terminated Not applicable Interventional

A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2

NCT01197963
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sleeve Gastrectomy and Ileal transposition, dietary and medical management
Procedure · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

NCT00616811
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, Sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
79
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Fatty Liver
Interventions
INT-747, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex

NCT03419195
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy, Overweight, Cardiovascular Risk Factor
Interventions
Cardiovascular exercise training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 15, 2026, 2:17 PM EDT
Enrolling by invitation Not applicable Interventional

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

NCT06542939
View directory record Official record
Conditions
Diabetes Mellitus Type II, Hypertension
Interventions
Integrated CHW Intervention, CHW Session 1 Only
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

Gastroparesis Registry 4

NCT05846802
View directory record Official record
Conditions
Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus Type I, Gastroparesis Due to Diabetes Mellitus Type II, Functional Disorder of Gastrointestinal Tract, Gastro-Intestinal Disorder
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Scottsdale, Arizona • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 15, 2026, 2:17 PM EDT
Terminated Phase 4 Interventional Results available

Simplified Insulin Regimen for the Elderly

NCT03660553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine, Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
University of Miami
Other
Eligibility
65 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Not applicable Interventional

Egg Ingestion in Adults With Type 2 Diabetes

NCT02052037
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Egg inclusion, Egg exclusion
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
35 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 15, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 15, 2026, 2:17 PM EDT